AstraZeneca and Galderma Pharma enter into R&D collaboration to develop new treatments for dermatological diseases
LAUSANNE, Switzerland—Global biopharma giant AstraZeneca and Galderma Pharma S.A., a global speciality pharmaceutical company focused on dermatology, have entered into a research and development collaboration to develop new treatments for dermatological conditions, such as psoriasis, acne and atopic dermatitis.
Under the terms of the five-year agreement, the financial terms of which were not disclosed, Galderma will have exclusive access to a number of compounds from across AstraZeneca's portfolio to develop in dermatological indications. Initial targets for collaboration have already been identified from disease areas as diverse as oncology, inflammation and central nervous system disorders. These will be interrogated based on translational science and preclinical testing to determine the ones that will progress in the collaboration.
"Galderma is committed to discovering, developing and delivering innovative solutions for dermatology patients and physicians," says Alain Jacot, vice president and chief scientific officer of Galderma. "This unique and exclusive collaboration with one of the world's leading pharmaceutical companies will complement Galderma's internal R&D efforts and significantly enhance our ability to make important new discoveries that have the potential to treat serious dermatologic disorders"
Clive Morris, head of the AstraZeneca business unit focused on new opportunities and innovative medicines, added: "This partnership is an example of how we are leveraging our science in new and creative ways through collaborations with recognized experts outside of AstraZeneca's core therapy areas. Partnering with Galderma, a world-leader in dermatology, is the most efficient and effective way to unlock the potential of our compounds in this rapidly evolving disease area."
Galderma, which has a strategic ambition is to be recognized as "the most competent and successful innovation-based company focused exclusively on meeting the needs of dermatology patients and physicians," was founded in 1981 and has more than 3,200 employees in 31 affiliates around the world. With approximately 20% of sales invested each year to discover and develop new products and access innovative technologies, Galderma's laboratory in Sophia-Antipolis, France, is said to be one of the largest R&D facilities in the world dedicated exclusively to dermatology.